1.Clinical Efficacy of Qi-regulating and Phlegm-removing Method(Liu Junzitang Combined with Linggang Wuwei Jiangxintang) in Treating AECOPD with Increased EOS
Renjie HUANG ; Wangqin YU ; Wuyinuo TANG ; Hong SONG ; Lyuyuan HE ; Wenbo LIN ; Guanyi WU ; Hang HUANG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(3):149-156
ObjectiveTo assess the efficacy and safety of the Qi-regulating and phlegm-removing method(Liu Junzitang Combined with Linggang Wuwei Jiangxintang) for treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with increased eosinophils (EOS). MethodsSixty-eight AECOPD patients with increased EOS who were hospitalized in the Department of Pulmonary Diseases of Jinhua Traditional Chinese Medicine Hospital from April 2023 to April 2024 were recruited and randomly assigned to an experimental group (EG) or a control group (CG). Both groups received conventional Western medicine, with the EG additionally receiving Liujunzitang and Linggan Wuwei Jiangxintang. The therapeutic efficacy indicators were measured after the treatment. The main therapeutic efficacy indicators included partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCO2). The secondary efficacy indicators included the TCM symptom scores, the COPD Assessment Test (CAT) score, the Modified Medical Research Council (mMRC) Dyspnea Scale score, and the length of hospital stay. The indicators were measured at baseline and on days 3 and 7 of intervention. The safety was evaluated based on the adverse events. ResultsBaseline characteristics were not statistically different between the two groups. Compared with CG, EG showed no significant difference in PaO2 (P=0.773), PaCO2 (P=0.632) and or CAT score (P=0.336) at on day 3 but better PaO2 (P=0.004), PaCO2 (P=0.008), and CAT score (P=0.013) were significantly better at on day 7. Compared with CGAfter treatment, EG had lower TCM syndrome scores of than CG EG on day 3 (P=0.005) and day 7 were significantly decreased (P0.001). There was no significant difference in mMRC score between the two groups on day 3 (P=0.514) and day 7 (P=0.176) as wasor the length of hospital stay (P=0.915). The generalized linear mixed model (GLMM) showed that compared with CG, EG had significant improvements over time in PaO2, PaCO2, TCM syndrome symptom scores, CAT score, and mMRC score. ConclusionRegulating qi Qi and removing phlegm combined with conventional Western medicine can significantly alleviateimprove the clinical symptoms and improve the lung function of AECOPD patients with increased EOS increased AECOPDwhich has and demonstrates good safety.
2.Clinical Efficacy of Qi-regulating and Phlegm-removing Method(Liu Junzitang Combined with Linggang Wuwei Jiangxintang) in Treating AECOPD with Increased EOS
Renjie HUANG ; Wangqin YU ; Wuyinuo TANG ; Hong SONG ; Lyuyuan HE ; Wenbo LIN ; Guanyi WU ; Hang HUANG
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(3):149-156
ObjectiveTo assess the efficacy and safety of the Qi-regulating and phlegm-removing method(Liu Junzitang Combined with Linggang Wuwei Jiangxintang) for treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) with increased eosinophils (EOS). MethodsSixty-eight AECOPD patients with increased EOS who were hospitalized in the Department of Pulmonary Diseases of Jinhua Traditional Chinese Medicine Hospital from April 2023 to April 2024 were recruited and randomly assigned to an experimental group (EG) or a control group (CG). Both groups received conventional Western medicine, with the EG additionally receiving Liujunzitang and Linggan Wuwei Jiangxintang. The therapeutic efficacy indicators were measured after the treatment. The main therapeutic efficacy indicators included partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCO2). The secondary efficacy indicators included the TCM symptom scores, the COPD Assessment Test (CAT) score, the Modified Medical Research Council (mMRC) Dyspnea Scale score, and the length of hospital stay. The indicators were measured at baseline and on days 3 and 7 of intervention. The safety was evaluated based on the adverse events. ResultsBaseline characteristics were not statistically different between the two groups. Compared with CG, EG showed no significant difference in PaO2 (P=0.773), PaCO2 (P=0.632) and or CAT score (P=0.336) at on day 3 but better PaO2 (P=0.004), PaCO2 (P=0.008), and CAT score (P=0.013) were significantly better at on day 7. Compared with CGAfter treatment, EG had lower TCM syndrome scores of than CG EG on day 3 (P=0.005) and day 7 were significantly decreased (P0.001). There was no significant difference in mMRC score between the two groups on day 3 (P=0.514) and day 7 (P=0.176) as wasor the length of hospital stay (P=0.915). The generalized linear mixed model (GLMM) showed that compared with CG, EG had significant improvements over time in PaO2, PaCO2, TCM syndrome symptom scores, CAT score, and mMRC score. ConclusionRegulating qi Qi and removing phlegm combined with conventional Western medicine can significantly alleviateimprove the clinical symptoms and improve the lung function of AECOPD patients with increased EOS increased AECOPDwhich has and demonstrates good safety.
3.Textual Research of Pediatric Famous Classical Formula Daochisan Based on Ancient and Modern Literature
Lyuyuan LIANG ; Hejia WAN ; Jinyan ZHANG ; Keke LIU ; Jialei CAO ; Xianghan TAN ; Bingqi WEI ; Bingxiang MA ; Yajing HE
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(11):218-227
Daochisan is a pediatric famous classical formula in traditional Chinese medicine(TCM) specializing in clearing the heart, disinhibiting water and enriching Yin, which has been inherited and developed by medical experts of successive generations. The formula can be traced back to Xiaoer Yaozheng Zhijue written by QIAN Yi from Song dynasty, and most of the later-developed Daochisan(Daochitang) is based on this formula with additions and subtractions. So as to promote the literature excavation of this formula, this paper conducts a thorough textual research and analysis of the composition, processing, preparation methods, clinical applications of Daochisan based on a systematic collation of relevant ancient and modern literature in the method of bibliometrics. A total of 127 pieces of data involving 86 antient TCM books were collected. Statistical analysis showed that the drug origin of Daochisan is basically clear, we suggest that Rehmanniae Radix is the root tuber of Rehmannia glutinosa of Scrophulariaceae, Akebiae Caulis is the dry stem of Akebia quinata of Lardizabalaceae, Glycyrrhizae Radix et Rhizoma is the dry root and stem of Glycyrrhiza uralensis of legume, bamboo leaf is the dry leaves of Phyllostachys nigra var. henonis of gramineous plants. Four herbs are recommended to use its raw products. The key information of the dosage and decocting method is supposed to be "4.13 g each of raw Rehmanniae Radix, raw Glycyrrhizae Radix et Rhizoma, Akebiae Caulis, adding 300 mL of water, and then adding 4.13 g of bamboo leaf, decocting together to 150 mL, taking warmly after meal". Daochisan has the effect of clearing the heart and enriching Yin, disinhibiting water and relieving stranguria, and is widely used in treating symptoms such as heart vexed hotness, hydrodipsia and reddish complexion. Modern studies have showed that Daochisan are frequently used in treating oral ulcer, herpetic stomatitis, urinary tract infection, herpes zoster and other diseases. The above research results can provide scientific reference for the future development and research of Daochisan.
4.Textual Analysis of Classic Formulas Yinchenhao Tang Based on Ancient and Modern Literature
Qing HE ; Lyuyuan LIANG ; Jialei CAO ; Yulu BIAN ; Bingqi WEI ; Chongyi HUANG ; Hejia WAN ; Bingxiang MA ; Wenli SHI
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(12):158-165
Yinchenhao Tang has definite clinical efficacy. It has been inherited and documented since the ancestor of Shanghanlun in the Eastern Han dynasty and is a classical formulas for clearing away heat, promoting diuresis, and eliminating jaundice adopted by medical experts of successive generations. It has been included in the Catalogue of Ancient Classical Formulas (the Second Batch of Han Medicine) published by the National Administration of Traditional Chinese Medicine (TCM) in 2023. By means of bibliometrics, 801 pieces of ancient literature data related to Yinchenhao Tang were collected, and 36 pieces of effective data were selected, involving 36 ancient books of TCM. The origin, name, composition, efficacy, formula and meaning analysis, drug origin, dosage, preparation method and usage, indications, and modern clinical application of Yinchenhao Tang were analyzed. It was suggested that the modern dosage and application of Yinchenhao Tang should be as follows: The 82.8 g of Artemisiae Scopariae Herba, 12.6 g of Gardeniae Fructus, and 27.2 g of Rhei Radix et Rhizoma. The formulas was prepared by firstly adding 2 400 mL of water into Artemisiae Scopariae Herba and boiling it to about 1 200 mL, then adding Gardeniae Fructus and Rhei Radix et Rhizoma to boil it for 600 mL, and removing the residue. It could be orally taken for 200 mL each time in warm conditions, three times a day. Yinchenhao Tang has the effect of clearing away heat, promoting diuresis, and eliminating jaundice, and it mainly treats symptoms of hygropyretic jaundice. In the formulas, Yinchenhao Tang is the monarch drug, which is mainly to remove dampness and jaundice. Gardeniae Fructus is the ministerial drug, which is mainly responsible for clearing the triple energizer and facilitating urination. Rhei Radix et Rhizoma is an adjuvant, mainly responsible for clearing away heat and eliminating jaundice. The modern application of this formulas involves the hepatobiliary system, skin system, endocrine system, digestive system, etc., and it has more advantages in treating jaundice, icteric hepatitis, and hepatitis B. In this study, the ancient literature related to Yinchenhao Tang was sorted out to determine its key information, so as to provide a scientific reference for clinical application of classic formulas and new drug development.
5.Textual Research on Classical Formula Juanbitang
Lyuyuan LIANG ; Jinyan ZHANG ; Jialei CAO ; Hejia WAN ; Tongyi HUANG ; Mengmeng GENG ; Bingqi WEI ; Bingxiang MA ; Yajing HE
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(24):190-197
This paper discussed the historic evolution of Juanbitang and similar decoctions, clarified the historic development of Yangshi Juanbitang and Chengshi Juanbitang, and probed into the key information of the meaning, original plants, processing methods, and modern dosage and usage of Chengshi Juanbitang. A total of 267 pieces of relevant information were collected from ancient traditional Chinese medicine (TCM) books, among which 53 pieces of effective data were included in this study. The results showed that both Chenshi Juanbitang and Yangshi Juanbitang were originated from Duhuo Jishengtang recoded in the Important Prescriptions Worth a Thousand Gold for Emergency (Bei Ji Qian Jin Yao Fang). According to the standard of "1 qian roughly equals 3.73 g" in the measurement system of the Qing Dynasty, we suggest Chenshi Juanbitang is composed of 3.73 g Notopterygii Rhizoma et Radix, 3.73 g Angelicae Pubescentis Radix, 3.73 g Gentianae Macrophyllae Radix, 11.19 g Angelicae Sinensis Radix, 11.19 g Mori Ramulus, 2.61 g Chuanxiong Rhizoma, 1.87 g Cinnamomi Cortex, 1.87 g stir-fried Glycyrrhizae Radix et Rhizoma, 7.46 g Piperis Kadsurae Caulis, 2.98 g Olibanum, and 2.98 g Aucklandiae Radix, which should be decocted with 600 mL water to reach a volume of 300 mL. The decoction should be taken 3 times a day before meals. Juanbitang, a classical formula specialized for treating impediment diseases, has the effects of dispelling wind, removing dryness, and alleviating impediment to relieve pain. It can be used for treating vexing pain in body, spasm of nape and back, and heaviness in waists and legs. Modern studies have shown that Juanbitang can be used for treating rheumatoid arthritis, knee osteoarthritis, and periarthritis of shoulder. The above results served as a reference for the future development of Juanbitang.

Result Analysis
Print
Save
E-mail